IL6 and congenital rubella syndrome: CRS is a nonspecific immune activation that, in the setting of leukoproliferative disorders such as leukemias or lymphomas, can cause a massive immune response and toxicity via the release of inflammatory cytokines such as IL‐6, TNF‐a, and IFN‐g [3].